National Advisory Committee on Immunization (NACI): Statements and publications

Canadian Immunization Guide (CIG) chapter

• Bacille Calmette-Guérin (BCG) Vaccine

New statements

• None

Prioritization statements

• February 2021: Guidance on the prioritization of key populations for COVID-19 immunization
• December 2020: Guidance on the prioritization of initial doses of COVID-19 vaccine(s)
• November 2020: Preliminary guidance on key populations for early COVID-19 immunization
  • CMAJ – Key populations for early COVID-19 immunization: preliminary guidance for policy
  • BMJ – Navigating inequities: a roadmap out of the pandemic

Research priorities statement

• Archived: Research priorities for COVID-19 vaccines to support public health decisions [2020-07-15]
  • Refer to the current vaccine statement for research priorities.

Guidance documents

• October 2020: Recommendations on the Duration of the Post-vaccination Observation Period for Influenza Vaccination during the COVID-19 Pandemic
• September 2020: Guidance on the use of influenza vaccine in the presence of COVID-19
• August 2020: Guidance for influenza vaccine delivery in the presence of COVID-19
• May 2020: Interim guidance on continuity of immunization programs during the COVID-19 pandemic

Canadian Immunization Guide (CIG) chapter

• Diphtheria Toxoid

New statements

• 2018 - Update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
  • Literature review on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine: safety, immunogenicity and effectiveness
  • CCDR - Summary of the NACI update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine

Canadian Immunization Guide (CIG) chapter

• Haemophilus influenzae Type B Vaccine

New statements

• None

Canadian Immunization Guide (CIG) chapters

• Hepatitis A Vaccine
• Hepatitis B Vaccine

New statements

• 2017 - Update on the recommended use of hepatitis B vaccine
  • CCDR - Summary of the NACI update on the recommended use of hepatitis B vaccine
• 2016 - Update on the recommended use of hepatitis A vaccine
  • CCDR - Summary of the NACI statement update on the recommended use of hepatitis A vaccine

Canadian Immunization Guide (CIG) chapter

• Herpes Zoster (Shingles) Vaccine

New statements

• 2018 - Updated recommendations on the use of herpes zoster vaccines
  • Literature review on the immunogenicity of herpes zoster vaccines
  • CCDR - Summary of the NACI update on herpes zoster vaccines

Canadian Immunization Guide (CIG) chapter

• Human Papillomavirus (HPV) Vaccine

New statements

• 2017 - Updated recommendations on human papillomavirus (HPV) vaccine: 9-valent HPV vaccine 2-dose immunization schedule and the use of HPV vaccines in immunocompromised populations
  • NACI literature review for HPV immunization of immunocompromised populations
  • CCDR - Summary of the NACI update on the recommended use of HPV vaccine: Nine-valent HPV vaccine two-dose immunization schedule and the use of HPV vaccine in immunocompromised populations
• 2016 - Updated recommendations on human papillomavirus vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule
  • CCDR - Summary of NACI's updated recommendations on HPV vaccines: Nine-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule
• 2015 - Update on the recommended human papillomavirus (HPV) vaccine immunization schedule
  • Amendment to the 2015 "Update on the recommended human papillomavirus vaccine schedule"
  • CCDR - Summary of the National Advisory Committee on Immunization's update on the recommended human papillomavirus (HPV) vaccine immunization schedule

Current statement

• Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2020-2021
  • Recommendation on the Use of Live Attenuated Influenza Vaccine (LAIV) in HIV-Infected Individuals
  • Supplemental Statement - Mammalian Cell Culture-Based Influenza Vaccines - An Advisory Committee Statement (2020-21)
  • Recommendations on the Duration of the Post-vaccination Observation Period for Influenza Vaccination during the COVID-19 Pandemic
  • Recommendations on Fractional Influenza Vaccine Dosing

Guidance documents

• September 2020: Guidance on the use of influenza vaccine in the presence of COVID-19
• August 2020: Guidance for influenza vaccine delivery in the presence of COVID-19

New statements

• Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2019-2020
  • Literature review on the comparative effectiveness and immunogenicity of subunit and split virus inactivated influenza vaccines in adults 65 years of age and older (2018)
  • CCDR - Summary of the NACI literature review on the comparative effectiveness of subunit and split virus inactivated influenza vaccines in older adults (2018)
  • CCDR - Summary of the NACI seasonal influenza vaccine statement for 2019-2020
• Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2018-2019
  • Literature review on individuals with neurologic or neurodevelopment conditions and risk of serious influenza-related complications (2018)
  • Literature review update on the efficacy and effectiveness of high-dose (Fluzone^®High-Dose) and MF-59-adjuvanted (Fluad^®) trivalent inactivated influenza vaccines in adults 65 years of age and older (2018)
  • Supplemental statement - Afluria Tetra^®- An advisory committee statement (ACS) (2018)
  • CCDR - Summary of the NACI seasonal influenza vaccine statement for 2018-2019
• Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2017-18
  • Addendum - Influvac^®use in children (2017)
  • CCDR - Summary of the NACI seasonal influenza vaccine statement for 2017-2018
  • CCDR - Addendum to the NACI statement on seasonal influenza vaccine for 2017-18
• Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2016-17
  • Addendum - LAIV use in egg allergic individuals (2016)
  • Addendum - LAIV use in children and adolescents (2016)
  • CCDR - Summary of the NACI seasonal influenza vaccine statement for 2016-2017
• Canadian Immunization Guide chapter on influenza and statement on seasonal influenza vaccine for 2015-16
  • Literature review on Pediatric Fluad^®influenza vaccine use in children 6-72 months of age (2015)
  • CCDR - Summary of the NACI seasonal influenza vaccine statement for 2015-2016

Canadian Immunization Guide (CIG) chapter

• Measles Vaccine

New statements

• 2018 - CCDR - Updated NACI recommendations for measles post-exposure prophylaxis
• 2016 - Update on measles-mumps-rubella-varicella vaccine and febrile seizures

Canadian Immunization Guide (CIG) chapter

• Meningococcal Vaccine

New statements

• 2020 - The Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease
• 2015 - Update on quadrivalent meningococcal vaccines available in Canada
  • CCDR - Summary of the National Advisory Committee on Immunization's update on quadrivalent meningococcal vaccines available in Canada

Canadian Immunization Guide (CIG) chapter

• Mumps Vaccine

New statements

• 2016 - Update on measles-mumps-rubella-varicella vaccine and febrile seizures

Canadian Immunization Guide (CIG) chapter

• Pertussis Vaccine

New statements

• 2018 - Update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
  • Literature review on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine: safety, immunogenicity and effectiveness
  • CCDR - Summary of the NACI update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine

Canadian Immunization Guide (CIG) chapter

• Pneumococcal Vaccine

New statements

• 2018 - Update on the use of pneumococcal vaccines in adults 65 years of age and older - A public health perspective
• 2016 - Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older - Interim recommendation
  • CCDR - Summary of NACI statement: Interim recommendations on the use of pneumococcal vaccines in immunocompetent adults 65 years of age and older
• 2015 - Re-immunization with polysaccharide 23-valent pneumococcal vaccine (PNEU-P-23)
  • CCDR - Summary of the National Advisory Committee on Immunization's statement on the re-immunization with polysaccharide 23-valent pneumococcal vaccine

Canadian Immunization Guide (CIG) chapter

• Poliomyelitis Vaccine

New statements

• None

Canadian Immunization Guide (CIG) chapter

• Rabies Vaccine

New statements

• None

Canadian Immunization Guide (CIG) chapter

• Rotavirus Vaccine

New statements

• 2016 - Statement on rotavirus vaccines and intussusception

Canadian Immunization Guide (CIG) chapter

• Rubella Vaccine

New statements

• 2016 - Update on measles-mumps-rubella-varicella vaccine and febrile seizures

Canadian Immunization Guide (CIG) chapter

• Smallpox Vaccine

New statements

• None

Canadian Immunization Guide (CIG) chapter

• Tetanus Toxoid

New statements

• 2018 - Update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine
  • Literature review on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine: safety, immunogenicity and effectiveness
  • CCDR - Summary of the NACI update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine

Canadian Immunization Guide (CIG) chapter

• Varicella (Chickenpox) Vaccine

New statements

• 2016 - Updated recommendations for the use of varicella zoster immune globulin (VarIg) for the prevention of varicella in at-risk patients
• 2015 - Varicella proof of immunity - 2015 update

New statements

• 2020 - Interim Statement on the Use of the rVSVΔG-ZEBOV-GP Vaccine for the Prevention of Ebola Virus Disease